Barely Significant
← all excerpts

Favipiravir: A new and emerging antiviral option in COVID-19.

Med J Armed Forces India · 2020 · PMC7467067 · PMID 32895599

Europe PMCDOI
1
hedged sentence
0.0199
closest p · 0.4× alpha
0.0199
boldest claim

The sentences

showed a trendP = 0.0199actually significant
Post hoc analysis demonstrated that favipiravir-treated patients showed a trend toward clinical improvement at day 7 among those with moderate COVID-19 (71.43% vs 55.86%, 95% CI: 0.0271 to 0.2843, P = 0.0199) and earlier resolution of fever and cough (p < 0.0001).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.